379 related articles for article (PubMed ID: 27543366)
1. Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture.
Roach ES
Pediatr Neurol; 2016 Oct; 63():6-22. PubMed ID: 27543366
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
4. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis.
Jóźwiak S; Kwiatkowski D; Kotulska K; Larysz-Brysz M; Lewin-Kowalik J; Grajkowska W; Roszkowski M
J Child Neurol; 2004 Feb; 19(2):102-6. PubMed ID: 15072102
[TBL] [Abstract][Full Text] [Related]
5. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
6. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.
Roth J; Roach ES; Bartels U; Jóźwiak S; Koenig MK; Weiner HL; Franz DN; Wang HZ
Pediatr Neurol; 2013 Dec; 49(6):439-44. PubMed ID: 24138953
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature.
Tran LH; Zupanc ML
Pediatr Neurol; 2015 Jul; 53(1):23-30. PubMed ID: 26092412
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex.
Islam MP; Roach ES
Handb Clin Neurol; 2015; 132():97-109. PubMed ID: 26564073
[TBL] [Abstract][Full Text] [Related]
9. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
[TBL] [Abstract][Full Text] [Related]
10. [Characteristics of tuberous sclerosis in children].
Riquet A; Cuisset JM; Cuvellier JC; Joriot S; Petit F; Vallée L
Arch Pediatr; 2010 Sep; 17(9):1338-45. PubMed ID: 20709508
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.
Switon K; Kotulska K; Janusz-Kaminska A; Zmorzynska J; Jaworski J
IUBMB Life; 2016 Dec; 68(12):955-962. PubMed ID: 27797139
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors].
Ruiz-Falcó Rojas ML
Rev Neurol; 2012 May; 54 Suppl 3():S19-24. PubMed ID: 22605628
[TBL] [Abstract][Full Text] [Related]
13. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with Mammalian target of rapamycin inhibitors.
Prato G; Mancardi MM; Baglietto MG; Janis S; Vercellino N; Rossi A; Consales A; Raso A; Garrè ML
J Child Neurol; 2014 Sep; 29(9):NP54-7. PubMed ID: 24056156
[TBL] [Abstract][Full Text] [Related]
14. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex.
DiMario FJ; Sahin M; Ebrahimi-Fakhari D
Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
[TBL] [Abstract][Full Text] [Related]
16. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
18. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors].
Zitterbart K
Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis complex: Recent advances in manifestations and therapy.
Wataya-Kaneda M; Uemura M; Fujita K; Hirata H; Osuga K; Kagitani-Shimono K; Nonomura N;
Int J Urol; 2017 Sep; 24(9):681-691. PubMed ID: 28667702
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
